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Abstract
Background: Healthy farm animals have been found to act as a reservoir of extended-spectrum β-lactamase
(ESBL)-producing Escherichia coli (E. coli). Therefore, the objective of the study was to determine the input of
antimicrobial active ceftiofur metabolites in the stable via faeces and urine after intramuscular administration of the
drug to pigs and the elucidation of the Escherichia coli ESBL resistance pattern of treated and untreated pigs
housed in the same barn during therapy.
Methods: For determination of the minimal inhibitory concentration (MIC) the method of microdilutionaccording
to the recommended procedure of the Clinical and Laboratory Standards Institute was used. Inaddition to that, a
qualitative determination was performed by agar dilution. Unsusceptible E. coli speciesselected via agar dilution
with cefotaxime were confirmed by MALDI-TOF and ESBL encoding genes wereidentified by PCR.
The amounts of ceftiofur measured as desfuroylceftiofur (DFC) in the different probes (plasma, urine, faeces and
dust) were analysed by UPLC-MS/MS.
Results: In a first experiment two groups of pigs (6 animals per group) were housed in the same barn in two
separated boxes. One group (group B) were treated with ceftiofur according to the licence (3 mg/kg administered
intramuscularly (i.m.) on three consecutive days, day 1–3). During a second treatment period (day 29–31) an increased
rate of ESBL resistant E. coli was detectable in these treated pigs and in the air of the stable. Moreover, the second
group of animals (group A) formerly untreated but housed for the whole period in the same stable as the treated
animals revealed increased resistance rates during their first treatment (day 45–47) with ceftiofur. In order to investigate
the environmental input of ceftiofur during therapy and to simulate oral uptake of ceftiofur residues from the air of the
stable a second set of experiments were performed. Pigs (6 animals) were treated with an interval of 2 weeks for
3 days with different doses of ceftiofur (3 mg/kg, 1 mg/kg and 0.3 mg/kg i.m.) as well as with 3 mg/kg per os) and the
renal and biliary excretion of ceftiofur as its active metabolite were measured in comparison to the plasma levels. In
addition to that, probes of the sedimentation dust and the air of the stable were analysed for drug residues.
Conclusion: The present study shows that treatment of several animals in a stable with ceftiofur influences the
resistance pattern of intestinal Escherichia coli of the treated as well as untreated animals housed in the same stable.
During therapy with the drug which was administered by injection according to the licence we detected nameable
amounts of ceftiofur and its active metabolites in the dust and air of the stable.
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Background
Antimicrobial resistance is a worldwide serious problem
in human and veterinary medicine. Therefore a series of
World Health Assembly resolutions [1] have been adopted
in order to enforce the development of the WHO global
strategy 2001 [2], the EU Antimicrobial Resistance Strategic
Action plan (2011) [3] and the EU Council Conclusions
(2012) [4]. As a result of these activities a lot of studies
were initiated concerning the development, spread and
occurrence of bacterial resistance in human and veterinary
medicine. Recently healthy farm animals have been
found to be a reservoir of extended-spectrum β-lactamase
(ESBL)-producing Escherichia coli (E. coli) with a preva-
lence of 10.7 to 36.3 % in pigs [5]. Such isolates have been
found in farm animals and pets in different countries
[5–9]. From farm animals the most common type of
ESBL gene of E. coli belongs to the CTX-M group
conferring resistance to third- and fourth-generation
cephalosporins [10, 11]. Indeed, it has been shown
that ceftiofur and cefquinome exerted selective effects
beyond the withdrawal times for CTX-resistant coliforms
due to proliferation of indigenous CTX-M producing
strains and by horizontal gene transfer [12]. Due to the
horizontal transfer by plasmids, transposons and integrons
resistance genes could be exchanged very fast and between
different bacterial species [13]. Thus, ESBL-producing
E. coli are held to be responsible for the broad occurrence
[14] and for severer courses of many diseases [15, 16]. In
recent years several studies were published in which the
application of antibiotics in livestocks cause the increase
of resistance [17, 18]. Thus, an enhancement of selective
pressure can influence the situation of resistance [19–21]
and strengthens the development and dissemination
of resistance in livestock populations [22].
In addition to the impact of antimicrobials on the
microbiome of treated animals the usage of antibiotics
applied with feed involves a high risk of environmental
pollution induced by drug residues. A study performed
by ZESSEL [23] revealed concentrations of sulfadiazin
up to 1.9 μg/mg in stable dust depending on position of
collecting and feeding formulation. This environmental
input of antimicrobials can be incorporated by animals
standing in the same stable with the result of detectable
drug levels in plasma and urine [23, 24]. But not only
the application of drugs via feed is an explanation for
the occurrence of antimicrobial residues in the environ-
ment, the study of SCHERZ et al. [25] revealed that the
drug and its metabolites are even present in sedimentation
dust and aerosol becoming bioavailable via excrements of
the treated animals.
Ceftiofur is a third-generation cephalosporin licensed
in Germany for the treatment of bacterial respiratory
diseases in swine and cattle as well as of interdigital
necrobacillosis and postpartum metritis in cattle [26].
After intramuscular application ceftiofur is quickly me-
tabolized to desfuroylceftiofur (DFC) by elimination of
furoic acid [27, 28]. Due to the integrity of the β-lactam
ring this metabolite still retains antibacterial activity [29].
DFC rapidly forms conjugates with plasma and tissue
proteins [30] or is metabolized to disulfides like DFC-
gluathione disulfide, DFC-cysteine disulfide or DFC-Dimer
[29]. All conjugates can be deconjugated to DFC and
therefore recover antimicrobial activity [31].
The aim of the study was to investigate the input of
ceftiofur in the stable after intramuscular injection of
the drug and the observation of the resistance situation
of the gut microbiome of swine. Furthermore occurrence
of ESBL-producing E. coli after an approved treatment
with ceftiofur and the influence on untreated animals of
the same barn was investigated. For this the transfer of
resistant bacteria or the exposure to minimal concentra-
tions of the active substance originating from the excre-
tion of treated pigs were considered.
Methods
Animals
At an age of four weeks healthy pigs (weight range from
8 to 9.2 kg) were kept after random allocation to two
groups (each of six) in a stable for the first part of the
experiment (experiment I) in which the development of
resistant E. coli in treated and non-treated animals was
investigated. The animals were fed with piglet starter
food and had free access to water. Before starting the
experiment rectal swab samples were taken from each
animal and the presence of ESBL resistant E. coli were
checked in the gut microbiome of the animals by an
enrichment-procedure and agar dilution. In the second
part of the experiment (experiment II) six female pigs
weighing 10 to 11 kg were used.
All animal studies were conducted according to insti-
tutional guidelines for ethical care and use of animals for
experimental and other scientific purposes. The study
was registered by the Lower Saxony State Office for
Consumer Protection and Food Safety (registry number:
33.12-42502-0-11/0338, Lower Saxony State Office for
Consumer Protection and Food Safety). The registration
procedure contains an approval of an internal ethic
committee.
Experimental design
In the first part of the experiment the influence of cef-
tiofur on the intestinal microbiota of the pigs was inves-
tigated. For the experiments a barn with dimensions of
4.8 m × 1.9 m was divided in two boxes via a middle cor-
ridor (width 1.60 m). As result of this areal separation a
direct contact of the grouped animals was excluded. To
minimize points of contact between both animal groups,
each box had its own stable equipment for cleaning and
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feeding. Protective clothing consisting of one-way overalls,
gloves and over boots were used in addition to the work-
ing clothes for each entry in the stable. Afterwards the
one-way articles were depolluted. To avoid a possible
cross-contamination the handling and maintenance of the
animals always start with the control group (group A).
The first group of animals (group A) served as
antimicrobial-free control group and was not treated
until day 45 of the experiment. To study the influence of
a therapeutic dosage on the physiological enteric micro-
biota the swine of the second group (group B) were
treated with 3 mg/kg/day ceftiofur hydrochloride on
three consecutive days (day 1 to 3) and for a second
time on days 29 to 31. For investigation of a possible
impact of an antibiotic application on pre-exposed but
formerly untreated animals the animals of the control
group (group A) were treated on day 45 to 47 for the
first time. Probes (faeces, dust and aerosol probes for
MIC determination) were collected on the following
days: 0, 5, 8, 14, 21, 28, 34, 37, 42, 50, and 53.
For collecting of dust of the stable filter pumps were
used and in addition to that, samples were drawn by
agar plates to observe the resistance situation of the en-
vironmental E. coli in the stable. Two of these pumps
(flow range between 2.7 L/min and 3.625 L/min ) with
sterile polycarbonate filters were placed at a distance of
30 cm from the treated group (group B) at the middle
corridor. After running for 1 hour filter membranes
from the pumps were transferred into 5 mL of Fluoro-
cult®-LMX-broth (LMX-broth modified acc. to Manafi
and Ossmer; Merck, Darmstadt, Germany) using a sterile
tweezer. In addition two opened endo-agar plates (lactose-
fuchsin-sulfite agar, Merck) were set on the brink of each
box in the stable for 1 hour (height 1 m).
For the second part of the experiment (experiment II),
only one box of the stable was used for six pigs. These
experiments were performed in order to elucidate the
input of ceftiofur residues into the stable due to biliary
and renal excretion of animals treated with different
dosage regimes. In addition, oral uptake of ceftiofur resi-
dues via air was simulated by a per os treatment with
3 mg/kg ceftiofur. To measure the excretion of DFC and
its metabolites animals (n = 6) were treated in an interval
of 2 weeks each time with different doses of ceftiofur
(3 mg/kg, 1 mg/kg, and 0.3 mg/kg) i.m. as well as 3 mg/kg
p.o. via feed three times every 24 h. For per os treatment
the amount of ceftiofur was added to some sugar cubes
and given to the animals.
Urine and faeces were collected separately on different
days (day 0, 1–3, and 7, 9, 11). These samples were
spontaneous excreted and placed into plastic tubes. In
addition to that, sedimentation dust was collected from
five different positions of the stable by using brand-new
playing cards at the same days (see above). Four of these
positions were close to the treated animals at the win-
dow ledge (position 1), partition grid (positions 2 and 3),
and the ground beside the box (position 4). A distance
of 1.60 m was between collecting position five and the
box of the animals. To collect aerosols filter pumps were
used for 8 h per sampling day by using polycarbonate as
filter material. They were arranged at two positions close
to the box. Dust and filters were placed into glass vials
and covered with metal foil. All samples were stored
light-protected at −20 °C until preparation.
Plasma samples of each treatment cycle were obtained
directly before and at various time intervals after the
injection of ceftiofur via syringe from the jugular vein.
After i.m. injection blood samples were taken at 0, 24,
and 48 h, whereas blood samples after per os application
were collected at 0, 2, 4, 6, 24, 48, 50, 52, 54, 71, and 96 h.
After centrifugation at 4 °C (3000 x g) for 10 min plasma
was collected from blood samples and stored at −80 °C.
Antibiotics
Ceftiofur (ceftiofur hydrochloride, ready to use product;
Vétoquinol) was administered by intramuscular (IM)
injection in the musculus trapezius of the neck. For
measuring the concentration of DFC and DFC-metabolites
in plasma ceftiofur sodium (ceftiofur sodium, sterile
powder; Excenel®) was applicated.
Isolation and MIC-determination of non-type-specific E.coli
The detection of the minimal inhibitory concentration
(MIC) followed the “performance standards for anti-
microbial disk and dilution susceptibility tests for bac-
teria isolated from Animals”-M31-A2 of the Clinical and
Laboratory Standards Institute [32]. The method of
microdilution was used. Microtiterplates containing serial
dilutions of ceftiofur concentrations from 0.125 μg/mL up
to 64 μg/mL (final concentration after inoculation) were
made in the laboratory and stored in a freezer at −70 °C.
Mueller-Hinton II broth was used for dilution.
Within 1 hour after sampling 1 g of faeces were homog-
enized in 9 mL of sterile physiological sodium-chloride
solution, streaked onto endo-agar plates and incubated for
24 h at 37 °C.
For the examination of susceptibility, subcultures of at
least ten single colonies, morphological typical for E.
coli, were sub-cultured on Mueller-Hinton-agar. The
susceptibility tests were always performed with colonies
from overnight plates. An inoculum of 5 × 105 colony
forming units (CFU)/mL per well, adjusted by densioto-
metry to 0.5 McFarland turbidity standard with Mueller-
Hinton-II-broth, was transferred to microdilution plates.
To protect the filled trays against dehydration during
incubation at 37 °C for 20–24 h the plates were cov-
ered with an adhesive foil [33]. For a positive control
the reference strain ATCC 25922 was used and MICs
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were compared to the required MIC reference range
(0.25 μg/mL to 1 μg/mL). Furthermore, a control for
growth and a negative control were conducted for
each colony. To determine CFU’s in inoculum suspensions
a dilution of each applied inoculum was plated on Cystine-
Lactose-Electrolyte Deficient (CLED)-agar. A number of
20–80 CFU [33] was set as reference range. The purity of
the inoculum was currently checked. To confirm the pres-
ence of E. coli in the examined samples an aliquot of each
CFU was transferred into Fluorocult® LMX Broth. A color
change of the broth from yellow to blue, a blue fluores-
cence under long-wave UV light and a positive indole
reaction with Kovacs reagent was regarded as highly
specific for E. coli. Only bacterial colonies which ful-
filled all these criteria were further evaluated and the
MIC-values determined.
In addition to a quantitative examination with micro-
dilution a qualitative determination was performed by
agar dilution. A 1:10 dilution in Lysogeny broth LB-
medium of each fecal sample and sampling day was in-
cubated at 37 °C for 24 h and 10 μL of the culture was
plated on endo-agar plates containing certain ceftiofur
concentrations (0 μg/mL, 1 μg/mL, 2 μg/mL, 8 μg/mL).
For confirmation of E. coli Fluorocult LMX broth in
combination with Kovacs reagent was used.
Verification of ESBL producing E. coli
After selection of unsusceptible E. coli via agar dilution
with cefotaxime containing MacConkey-agar (1 μg/mL),
the species was confirmed using MALDI-TOF identifica-
tion (MALDI Microflex ® LT and Biotyper ® database,
Bruker Daltonics, Bremen, Germany). Identification of
ESBL encoding genes of the CTX-M, TEM, SHV and
CYM families was carried out by PCR according to the
method published by Roschanski et al. [34].
Isolation and detection of E. coli in the environment
At the same day of sampling (see description of
experiment I) uncovered endo-agar plates were
placed in the stable. After 1 hour these plates were
closed and incubated for 24 h at 37 °C. Five colonies
per plate were selected and MIC’s determined by
microdilution.
The filter membranes of the filter pumps were
transferred in Fluorocult LMX broth and following an
enrichment of the bacteria at 37 °C for 24 h the
growth of E. coli was examined by color change, blue
fluorescence and positive indole reaction. In the case
of growth 10 μL of the suspension were plated on
endo-agar containing different concentrations of ceftiofur
(0 μg/mL, 0.5 μg/mL, 1 μg/mL, 2 μg/mL, 8 μg/mL). After
incubation (37 °C for 24 h) the growth of CFU of E. coli
was evaluated.
Analysis of desfuroylceftiofur (DFC) in the environment
Pretreatment of samples
To avoid excessive amounts of DFC all urine samples of
the dosing days (1 to 3) were diluted 1:100.
To 1 mL of urine, 150 mg faeces, 4 mg dust and the
filter from the air pumps 7 mL extraction solution
[sodiumtetraborat-decahydrat (0.95 % w/v), dithiothreitol
(0.23 %w/v)] were added. The samples were vortexed
and placed in a water bath at 50 °C for 15 min. Each
3 min the tubes were inverted. Subsequently after adding
of 1.5 mL derivatization solution [sodiumhydroxid solu-
tion (3.5 %w/v), iodoacetamid (5 %w/v)] to the sample,
the dilutions were vortexed again and mixed gently in
the dark at room temperature for 1 h. After adding of
250 μL acetic acid in water (20 % v/v) the samples were
centrifuged for 10 min (4 °C, 3000 × g).
For solid phase extraction (SPE) all cartridges were
cleaned, preconditioned with 2 mL of a solution of
acetonitrile in water (1:1) and afterwards preconditioned
using 2 mL bidest water. The following extraction proto-
col was used: the whole supernatant was applied to SPE
columns and unbound sample components removed by
washing with 3 mL bidest. After drying the column by
applying vacuum for 15 s, the analytes were eluted using
1.5 mL of a solution of acetonitrile and bidest (1:1) into
a test tube. The eluate was concentrated to a volume of
0.5 mL via SpeedVac® (Eppendorf, Hamburg, Germany),
transferred to an autosampler vial and finally filled up to
a volume of 1 mL with bidest.
The calibration of DFC was accomplished by pre-
treatment of ceftiofur sodium (Excenel®) according to
the above mentioned protocol. For each specimen
(plasma, urine, dust and faeces) matrix matched cali-
brations were prepared.
Analytical method
The amounts of DFC were analyzed with ultra-
performance liquid chromatography (UPLC) in combin-
ation with tandem mass spectrometric detection (MS/MS).
All detections were performed on an UltiMate 3000 RSLC
(Thermo Fisher Scientific, Dreieich, Germany) coupled to
a 5500 QTRAP mass spectrometer (AB Sciex, Darmstadt,
Germany) equipped with an ESI Turbo Ion Spray
source. For separation by liquid chromatography a
Acquity BEH C18 separation column, (50 mm× 2.1 mm,
1.7 μm, Waters) connected to a VanGuard BEH Shield
RP18 (1.7 μm) pre-column at 60 °C was used in gra-
dient elution mode. The mobile phase consisted of
eluent A (water, 0.1 % formic acid) and eluent B
(acetonitrile, 0.1 % formic acid) at a flow rate of
900 μL/min. The gradient of Eluent B was: 0 min
5 %; 0 min 5 %; 1.5 min 20 %; 1.6 min 50 %; 2.1 min
50 %; 2.2 min 5 %; 3 min 5 %. The injection volume
of each sample amounts to 5 μL.
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For DFC quantification mass spectral data were ac-
quired in positive ion electrospray ionization (ESI) mode
using the multiple reaction monitoring (MRM) scan
mode. Optimized ESI-MS/MS-dependent parameters
were as following: ion spray voltage 5.5 kV, ion source
gas 1, ion source gas 2, curtain gas, collision gas 40, 60,
20, medium (arbitrary units), respectively. The ion source
was run at a temperature of 600 °C. The precursor ion for
DFC was the ([M +H]+) ion of m/z 487.0. Characteristic
product ions were at m/z 241.0, 227.0, and 210.0
completing the MRM-transitions for DFC quantifica-
tion. Declustering potential, entrance potential and
collision cell exit potential experiments were optimized
and set to 120 V, 7 V, 13 V, respectively. By using
weighted (1/x) least-squares regression analysis the
calibration curves were obtained.
Statistical analysis
Results of the MIC determination by microdilution were
analysed with Exact Fischer Test using Microsoft Excel
software (Office 2007). Statistical significance was
assumed at p-values of ≤ 0.05.
Results
Microbiological studies (experiment I)
For discrimination between susceptible or resistant E.
coli the epidemiological cut-off (Ecoff ) and the clinical
breakpoint (cbp) were used. For E. coli and ceftiofur the
Ecoff was set to ≤ 1 mg/L [35]. Both EUCAST and CLSI
could not fix a clinical breakpoint for ceftiofur and
swine. Nevertheless for cow the a cbp of ≥ 8 mg/L
was published by the CLSI in the “Approved Standard
M31-A2” document [32] and was adopted in place for
swine in this experiment.
Isolation and detection of E.coli in swine
On the day before ceftiofur was applicated for the
first time (day 0) only MICs below the Ecoff were de-
termined as expected. Up to day 28 exclusively CFUs
with MICs < 1 mg/L were detected by microdilution
without initial enrichment of the bacterial colonies in
the samples of all animals after the first treatment of
the animals of group B (Fig. 1a and b).
The results of both groups (untreated and treated) did
not differ and demonstrated the presence of the wild
type of E. coli. After the second treatment of group B
the results between both groups differed. While in the
samples of animals from the untreated group (group A)
no resistant CFUs were found, two animals of the treated
group showed three E. coli isolates with MICs > 64 mg/L
on day 34 (Fig. 1b). At the following sampling day
(day 37) two colonies with an increased MIC could
be found in the samples from this group of animals.
These E. coli differed from the wild type and could
be declared as resistant from an epidemiological stand-
point. On day 42 none E. coli with increased MICs were
found by microdilution.
Subsequent to the second treatment of group B, the
previously untreated animals of group A received ceftio-
fur (3 mg/kg i.m.) according to the market authorization
for the drug on day 45 to 47. In the fecal samples on day
50 of all 6 animals of this group 43 resistant CFUs in
total were determined. On day 53 the number of
measured CFUs, with an increased MICs dropped to
15 CFUs (Fig. 1b). Considering the results of microdilu-
tion a statistically significant difference (p < 0.001) was
observed between the number of resistant CFUs in the
samples from the treated group B after its first and sec-
ond treatment compared to group A after its treatment.
The simultaneously performed agar dilution assay
(Fig. 1c) revealed in none of the fecal samples E. coli
with an increased MIC (>1 mg/L) on day 0 of the experi-
ment and confirmed the absence of resistant E. coli in
the gut microbiome of the animals in both groups. The
same results were received for the days 5, 8 and 14. On
day 21 with the aid of an enrichment procedure in
one swine of group A E. coli with a MIC of > 2 mg/L
(but < 8 mg/L) were detected. The presence of resistant E.
coli in this animal could not be demonstrated on the fol-
lowing days of sampling (day 28 and 34). Resistant E. coli
(>1 mg/L) were found on day 28 in two fecal samples of
group B and in one of group A. The presence of non-wild
type E. coli was demonstrated on day 34 in all samples of
the treated group and in three of the other group after the
second treatment of group B. Resistant E. coli were found
in the fecal samples of all animals on day 42. In these cefo-
taxim resistant bacteria the genes of the enzyme families
TEM and CTX-M were detected by PCR (data not
shown). Occurrence of the TEM genotype does not con-
firm the presence of ESBL because not every derivate of
this enzyme is responsible for resistance to oximino-
chepalosporins whereas all enzymes of the CTX-M family
possess the ESBL phenotype.
Isolation and detection of E.coli in the environment
At the beginning of the experiment it was not always
possible to isolate E. coli from the environment either by
endo-agar plates or by air pumps (Fig. 2).
By using endo-agar plates (Fig. 2a) the first bacterial
colonies were obtained on day 8 (n = 1) and day 14 (n = 1)
of the experiment from the area of the animals of group B
(location 2 of the endo-agar plate) and on day 21 from
area of group A (n = 2, location 1). In the course of the
experiment the number of E. coli CFUs increased. Within
the interval between the first and the second treatment of
the animals of group B 3 to 5 CFUs per sampling day and
location were detected. In this timeframe all MICs of these
E. coli were below the Ecoff, with the exception of one
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Fig. 1 Results of the microbiological studies (experiment I). a Results of microdilution assay, detection of MIC-values of 10 E. coli colonies per animal and
sampling day (left red Boxplot: group A (n= 6 animals), right black boxplot: group B, n= 6 animals) after treatment of pigs; Ecoff: epidemiological cut-off
(≤1 mg/L) ; cbp: clinical breakpoint (≥8 mg/L). b Overview about the number of examined CFU, number of detected CFU with MIC >1 mg Ceftiofur/L and
number of swine with increased MICs. Starting at day 34 the numbers on the left side of each field in the table stands for the value of group A, whereas
the second value stands for group B. c Results of agardilution assay; green box: MIC < 1 mg Ceftiofur/L, red box: MIC > 1 mg/L
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colony on day 14 and 21 each in the area of the treated
animal group. After the treatment of the formerly un-
treated group A (treatment days 45 to 47) E. coli with in-
creased MICs (≥64 mg/L) were recovered. In the location
of the group B two of five tested CFUs and in the area of
group A all five CFUs showed these high MIC values.
With filter pumps (Fig. 2b) E. coli with MICs of > 8 mg/L
were already selected on day 34 to 42. In the period after
treatment of the group A the same results were received.
Excretion of antimicrobial active metabolites and its
transfer into environment (experiment II)
For a comparison of biliary and renal elimination rates
of the drug under different doses regimes and in order
to investigate the input of drug residues in aerosol and
dust of the stable via excrements of treated animals a
pharmacokinetic study was performed after i.m. application
of 0.3, 1, and 3 mg/kg ceftiofur. In addition to that, ceftiofur
(3 mg/kg) were given per os to simulate oral uptake
of active drug residues via the air of the stable.
Validation of analytical parameters
The development of the MRM-assay included the deter-
mination of major analytical parameters for DFC
quantification in different matrices. Thereby LOD and
LLOQ were determined in respective artificial matrices by
extrapolation after adding ceftiofur (1 ng/mL) and subse-
quent sample preparation as described in the experimental
section. The LOD for the quantification of DFC was calcu-
lated to be in the low ng/mL-range (Additional file 1: Ana-
lytical validation, Table S1).
Linearity of method for the matrix matches calibrations
was tested for a concentration range of 1–500 ng/mL with
acceptable regression values as depicted in the Additional
file 1: Analytical validation, Figure S1. The coefficients of
variation (CV) for the intra-assay imprecision including
sample preparation of DFC from investigated sample
matrices were determined using two different concen-
tration levels (5 ng/mL and 100 ng/mL; n = 5 each).
As Additional file 1: Table S2 (Analytical validation)
illustrates obtained CV’s were in all matrices below
10 %, indicating a sufficient sample cleanup.
Plasma
Plasma concentrations of DFC depended on dosage and
treatment day (see Additional file 2). Thus DFC-
concentrations in plasma were lower after treatment
with 0.3 or 1 mg/kg in comparison to 3 mg/kg (i.m.).
A
B
Fig. 2 MIC-values of E. coli isolates collected by endo-agar plates by sedimentation (a) and by air pumps (b) in the stable after treatment of 6 animals
of each group with 3 mg/kg b.w. i.m. (experiment I). a Determination of MIC-values from single colonies (n = 5) isolated from uncovered endo-agar
plates via microdilution. Endo-agar plate 1 (location 1) was located in front of box A, whereas the second agar plate (location 2) was positioned besides
box B. b MIC-values of E. coli isolates form the air of the stable after enrichment and agardilution. Left air pump was positioned at the side of box A
and the second air pump was located close to box B
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The highest amounts of 13.53 μg DFC/mL and 17.28 μg
DFC/mL were observed 1 h after the first and third
intramuscularly injection of 3 mg/kg ceftiofur.
The low plasma concentrations of DFC and metabo-
lites (less than 0.1 μg/mL) after the oral treatment
showed a minor absorption rate via the intestinal tract
due to the chemical properties of ceftiofur.
Renal excretion
The elimination studies after intramuscular treatment of
swine with 0.3, 1, and 3 mg/kg ceftiofur showed that the
majority of the administered ceftiofur dose was excreted
via urine (see Additional file 3). Because of the different
drinking pattern of each animal the amount of creatinine
was measured and the concentration of DFC and DFC-
metabolites were normalized to these values. It is
obvious from the data, that the majority of ceftiofur is
eliminated during the treatment period and only minor
amounts are excreted afterwards. The low concentra-
tions of DFC in urine after oral application reflected the
poor oral absorption of ceftiofur and confirm the results
examined in plasma.
Biliary excretion
Since ceftiofur and its metabolites are eliminated primarily
by renal excretion low amounts were quantified in faeces
(see Additional file 4). The highest concentrations were
measured on day 2 and 3. On day 3 262.94 ng DFC/g faeces
was detected after intramuscular treatment with 3 mg/kg
ceftiofur. Corresponding to the former results the biliary
elimination was clearly dose-dependent. The poor
absorption rate of ceftiofur into the blood after per os
treatment resulted in high concentrations of DFC and
DFC-metabolites in faeces. The DFC-concentrations
measured on day 2 and 3 after oral treatment were
slightly higher than after intramuscularly application.
Sedimentation dust
Although ceftiofur was applicated by i.m. injection, residues
of DFC and metabolites were present in the sedimentation
dust samples (Fig. 3 and Additional file 5). Significant levels
of DFC were detected after intramuscularly treatment with
3 mg/kg and 1 mg/kg with up to 61.22 ng DFC/mg dust
(Additional file 5). During the application period the values
of DFC in dust increased. After treatment DFC-values de-
creased but were still detectable until day 11 in every sam-
ple of dust. The level of measured DFC-amounts depended
on the collecting position. Samples from the positions next
to the box of the animals (position 2 and 3) showed the
highest amounts. Lower concentrations of DFC were
detected in the dust at the ground in front of the box
(position 4) due to the presence of feed residues,
which accumulated in this area.
After the per os treatment lower amounts of DFC with
up to 4.86 ng DFC/mg were quantified in dust.
Fig. 3 Concentrations of DFC in sedimentation dust after treatment of six animals with 3 mg Ceftiofur/kgb.w. i.m. (experiment II). Samples of the
sedimentation dust were collected at different locations of the barn (position 1: window ledge, position 2: feeding trough, position 3: resting
place, position 4: ground between the boxes, position 5: opposite site of the boxes for the animals). DFC-concentrations were analyzed by mass
spectrometry. The arrows indicated the time points of treatment
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Aerosol
In all filter pump collected aerosol samples residues
of DFC and metabolites were detectable (Fig. 4 and
Additional file 6). Depending on the dosage, the highest
amounts were measured after intramuscular treatment with
3 mg ceftiofur/kg. On day 3 values up to 12.8 ng DFC/m3
air were quantified. After treatment with the lower dosages
(1 and 0.3 mg/kg i.m.) decreased amounts of DFC in the
aerosol samples were examined. As already shown very low
amounts of DFC were detectable in the aerosol samples of
the stable after oral treatment. Furthermore no residues
were measurable in the days after per os treatment.
Discussion
The study shows that treatment according to license of a
group of animals in a stable with the antimicrobial cef-
tiofur leads to an alteration of the resistance pattern of
the animals. Although administered by injection, active
drug metabolites were found in dust and aerosol of the
stable and also ESBL-carrying E. coli were detected in
the aerosol. But the key finding of the study was that not
only the treated animals from group B showed ESBL
resistant E. coli after the second application of ceftiofur.
For these ESBL resistant E. coli were also present in the
untreated animals of group A, whom were housed in the
same stable, during their first treatment. Therefore it is
indicated that either drug residues in the air of the stable
or ESBL resistant E. coli originated from the treated ani-
mals are the trigger for the resistance pattern of initially
untreated animals.
At day 34 of the experiment the first E. coli isolates
with MIC > Ecoff were detected in the group of treated
animals and later on all animals were affected. In this
context it should be noted that at the beginning of the
experiment the stable as well as all animals were E. coli
ESBL negative. Therefore, only two treatments with cef-
tiofur according to the license were sufficient to induce
a shift of the MIC of E. coli in these animals.
The occurrence of resistant E. coli bacteria under cef-
tiofur treatment can be explained by spontaneous muta-
tions of β-lactamase encoding genes or by acquisition of
resistance encoding genes from other bacteria of the gut.
The lactamases TEM-7, TEM-12 and SHV-2 are exam-
ples for lactamases which obtain the capability to inhibit
cephalosporins of the third generation as a result of a
change of one codon in the DNA [36]. At the beginning
of the experiment the microbiome of the animals was
examined only for resistant E. coli due to the use of
endo-agar. Thus, presence of other bacteria, e.g. non-E.
coli microbes, which carried ESBL-encoding genes can-
not be excluded. ESBL of the CTX-M family were found
in this study (data not shown). For this enzyme family it
is unlikely to be building up through single amino acid
alterations [37]. These lactamase encoding genes are
Fig. 4 Concentrations of DFC in the aerosol of the stable after treatment of six animals with 3 mg Ceftiofur/kg b.w. i.m. or 1 mg/kg b.w. i.m.
(experiment II). Via air pumps located near to the animals at the feeding through and on the left side of the resisting place probes of the aerosol
were sampled and the DFC content measured by mass spectrometry. For determination of the amount of the dust in the aerosol the filters were
weighted before and after the 8 h sampling period
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plasmid-mediated [38, 39] and exchanged by conjugation.
A study of Frye et al. [13] showed that most of ß-lactam
resistance genes were shared by different bacteria as dem-
onstrated for E. coli and Salmonella species. The presence
of plasmid mediated CTX-M ESBLs in this study is a
strong indication for acquisition of resistance genes by
horizontal transfer from other bacteria of the microbiome
in the treated animals.
Although ceftiofur was administered by intramuscular
injection, DFC as antimicrobial active metabolite was
found in the dust and aerosol of the stable. The only
way for the entry of these antimicrobial residues into the
environment of the stable was via urine and faeces.
Therefore concentration – time profiles of DFC were
measured in urine and faeces of the treated animals. To
our knowledge there are no data about the composition
of metabolites in faeces after a treatment with ceftiofur.
But in urine additional to the parental ceftiofur (28.3 %)
the major metabolites of ceftiofur are the DFC-dimer
(27,1 %) and DFC-cystein (32,3 %) [27]. All these metab-
olites retained their intact β-lactam ring and can be re-
duced back to DFC. Therefore about 88 % of the applied
ceftiofur dose is excreted in an antimicrobial active form
[40]. In a study by Gilbertson [41] microbiological activ-
ity for several days was found in urine samples. Conse-
quently drug residues were measured in sedimentation
dust and aerosols after detection of DFC and its metabo-
lites in urine and faeces. Based on the data of this study,
the primary route of drug entry into the vicinity of
ceftiofur treated animals seems to be via the urine.
Although a fast degradation of ceftiofur and its metab-
olites in faeces and urine was described [41] and it was
assumed that this drug is inactivated by the microbiota
of the colon during the biliary secretion [28], we could
show the entry and persistence of DFC and its metabo-
lites in the environment. Due to the presence of the
intact β-lactam-ring the detected metabolites retains
microbiological activivity [31]. It cannot be ruled out
that the top layer of the dust is vulnerable to photode-
gradation and thus also protecting the underlying layers,
which could be a mechanism for conservation of micro-
biological activity of the drug residues in these under-
lying layers [41]. In a study by Hamscher et al. [42]
antibiotic residues could be detected in 20 years old dust
samples from a stable. In the case of insufficient cleaning
of an animal stable after the treatment with antimicro-
bials potential residuals could be persist for a long time.
After treatment with 3 and 1 mg/kg ceftiofur (i.m.) the
highest amounts of the drug were found in dust. Higher
DFC-concentrations in dust after application of 1 mg/kg
ceftiofur in comparison to the 3 mg/kg dosage can be
explained by an increased activity of the animals because
the pigs were in growth during the experiment and the
lower dosage was tested afterwards. Due to the increased
activity of the older pigs more dried urine and feaces are
swirled up in the stable and leads to a higher DFC-
concentration in the aerosol.
Parallel to the detection of active DFC-metabolites in
dust and aerosol ESBL producing E. coli in the air of the
stable were identified. Moreover, the animals of the
formerly untreated group (group A) show clinically re-
sistant E. coli bacteria during their first treatment on day
45–47. These results indicate that either low amounts of
the drug in the stable or occurrence of E. coli carrying
the ESBL resistance from previously treated animals
(group B) in the air of the stable induce a MIC shift of
the E. coli from the untreated animals towards clinical
resistance. This implies that only two consecutive treat-
ments with ceftiofur were necessary to induce a resistant
phenotype in untreated animals housed in the same barn
as the treated animals.
The carry-over of antimicrobials like ceftiofur and
their active metabolites in the stable could facilitate the
development of antibacterial resistance due to ingestion
by untreated animals. These very low concentrations of
the antimicrobial in the gut of untreated animals could
promote a selection advantage to bacteria in which a few
point mutations within the genes give rise to the extended
spectrum phenotype [43]. A study performed by Zessel
[23] demonstrated that an oral medication of some pigs
with sulphadiazine resulted in a residual level in the envir-
onment that cause detectable amounts of this antibiotic in
the plasma of untreated pigs that were kept in the same
stable. On days 0, 3, and 4 of the experiment plasma sam-
ples of the untreated control group were taken and the
potential amount of DFC and its metabolites was deter-
mined. However, no residues could be detected in plasma
or were below the detection limit of the method. But the
lack of evidence of absorption of ceftiofur into the blood
plasma does not argue against the possibility that these
sub-therapeutic doses may have contributed to the devel-
opment of resistant E. coli in the untreated animals.
Detection of ESBLs of the CTX-M family in samples of
the control group may (group A) argue for the transfer of
plasmids or an exchange of resistant bacteria between the
two animal groups and could be also a reason for the re-
sistance of untreated animals. By using of group-owned
stable equipment and subsequent feeding the animals of
control group and the animals of the treated group, the
exchange of bacteria between both groups via the involved
personal or equipment was minimized. Therefore it can
be assumed that the transmission of bacteria occurred by
air or aerosols. Different studies [44–46] showed the tran-
sition of gram negative bacteria, mainly E. coli, in the air.
In our study E. coli were recovered from the environment
by use of air pumps and endo-agar plates to determine the
MIC. Within the first days of the study only a few CFU
were isolated. Higher room temperatures in combination
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with lower humidity in the stable may be an explanation
for this finding. Because of the age of the swine the stable
had to be heated to 24.5 °C in the first two weeks.
Mueller and Dinter [47] confirmed these both parameters
as factors influencing the tenacity of E. coli. Furthermore
the increased number of bacteria in the air of the stable
during the experiment can be a reason for a better recov-
ery as well. Zucker and Mueller [44] reported that faeces
are an origin of bacteria in the air. This is particularly sig-
nificant when it is assumed that during treatment with
ceftiofur bacteria of the intestinal microbiota acquired re-
sistance and were spread after excretion in the air inside
the barn. E. coli in the air with MIC > 64 mg/L in both
areas of the stable were detected. Therefore it can be
assumed that an exchange of bacteria occurred between
the two groups. The uptake of resistant bacteria from the
environment and integration into the gut microbiome
may be a conceivable explanation for the development of
resistant E. coli in the control group.
Without the presence of antibiotics, resistant bacteria
have no advantage in comparison to the wild type. A gen-
eral opinion is that through the acquisition of resistance
genes bacteria are subjected to a fitness loss and were dis-
placed by the wild type [48]. But the study of Jiang and
co-workers [49] showed the persistence of resistant bac-
teria in the microbiome of animals for a long time after a
treatment and demonstrated the possible integration of
resistant bacteria into the microbiome without a fitness
loss. It cannot be ruled out that very low concentrations
of DFC in the gut, ingested from the environment, sup-
ported the integration of these resistant bacteria into the
microbiome of the untreated animals without a fitness
loss. The impact on the intestinal microbiota by the use of
ceftiofur to these pre-stressed animals is obvious by com-
parison of the amounts of detected CFUs with MICs >
64 mg/L between the two animal groups. A statistically
significant difference (p < 0.05) was observed between
MICs of the untreated animals after application of ceftio-
fur and the results from treated animals after its first and
second treatment. Subsequent to the first use of ceftiofur
no CFU with increased MICs were detected in sam-
ples of the treated group (group B) with the microdi-
lution technique because no resistant E. coli was part
of the microbiome. During the experiment E.coli of
the gut acquired resistance encoding genes and CFUs
with increased MICs were found following a second
treatment. The intestinal microbiota of the animals
of the untreated group (group A) harboured resistant
E. coli at this time, but these were only detectable
after enrichment. Under the selective pressure of cef-
tiofur and their active metabolites in the gut during
the treatment of the control group (group A, day 45
to 47), such bacteria with ESBL encoding genes have
a selective advantage in growth while susceptible
bacteria will be inhibited. This growth benefit may
be an explanation for the high amounts of detected
resistant CFUs.
Conclusions
In conclusion, the use of ceftiofur in livestock leads to resi-
dues of DFC and other active metabolites in the
environment which are distributed through the whole
stable and influence the bacteria of the stable or can be in-
corporated by other animals of the livestock. In this study it
was shown that the treatment of several animals has an in-
fluence on the resistance situation of all individuals in the
barn. Thus, a prudent use of antimicrobials in a combin-
ation with good hygienic conditions is required and further
studies are necessary to investigate the role of intestinal E.
coli as a possible reservoir of antimicrobial resistance.
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